Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors.

press-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY-NC-ND Introduction Kidney cancer is amongst the ten most frequently diagnosed malignancies in men worldwide, 1 with more than 400,000 new cases per year, and an increasing trend for the incidence has been observed in European countries and in the younger population. 2 Renal cell carcinoma (RCC), the predominate type of kidney cancer, accounts for 2–3% of all adult malignancies. 3 Approximately 85% of all RCCs are clear cell tumours. 4 The remaining subtypes include papillary RCC, chromophobe RCC and oncocytoma as well as other minor subtypes.

also in 63,971 other papers